Portfolio Companies News
June 19, 2018Targovax granted EU Patent for muta...
Oslo, 19 June 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, announces that the European Patent Office has granted European Patent no 3079715, A Peptide... read more
June 18, 2018Nexstim Plc SmartFocusTM TMS techno...
Helsinki, 6/18/2018 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and commercializing its world-leading navigated non-invasive brain stimulation technology for therapeutic and diagnostic applications, provides an update on use of its... read more
June 17, 2018Aprea Therapeutics Presents Results...
June 17, 2018—Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm ORR (by IWG) of 100% in all... read more
June 13, 2018Nordic Nanovector Announces Archer-...
Oslo, Norway, 13 June 2018 Nordic Nanovector ASA (OSE: NANO) has received approval from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with Betalutin® (17... read more
June 12, 2018GenSight Biologics reports positive...
Clinically meaningful bilateral improvement of visual acuity supersedes observed and published natural evolution of the disease Bilateral improvement is not consistent with a placebo effect Statistically significant preservation of both retinal ganglion cells and temporal retinal nerve fib... read more
May 02, 2018Q1 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 111 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.